What specific medication forms does the Teva (NYSE:TEVA) agreement cover?

The licensing deal for Teva (NYSE:TEVA) covers both intravenous and subcutaneous forms of the ocrelizumab medication. Polpharma Biologics will handle the manufacturing of these specific treatment types.

What are the operational responsibilities for Teva (NYSE:TEVA) in this partnership?

Teva (NYSE:TEVA) will handle all regulatory submissions and direct commercialization efforts for the biosimilar. The company stated it will execute these operations across key global markets.

What role will Polpharma Biologics play alongside Teva (NYSE:TEVA)?

Polpharma Biologics will manage the direct development and physical manufacturing of the proposed biosimilar for Teva (NYSE:TEVA). This structure allows the partner company to focus strictly on commercial distribution.

Why did Teva (NYSE:TEVA) execute this biosimilar licensing transaction?

Teva (NYSE:TEVA) stated the agreement supports its broader Pivot to Growth business strategy. Management stated this specific initiative aims to increase overall global access to biologic medicines.

Image for illustrative purposes only. Not a real photo.

Teva signs global multiple sclerosis biosimilar agreement

Written by Brie CarterPublished Jul 9, 2026, 12:54 PM

Teva executed a global licensing agreement with Polpharma Biologics for a proposed multiple sclerosis biosimilar.
The company expects to handle commercialization and regulatory submissions across key global markets.
Management stated the partnership supports its broader corporate strategy to expand biologic medicine access.

Teva (NYSE:TEVA) signed a global licensing agreement with Polpharma Biologics for a proposed multiple sclerosis biosimilar.

The transaction covers both the intravenous and subcutaneous application forms of the ocrelizumab medication.

Polpharma Biologics will handle the primary development and physical manufacturing processes for the proposed medicine.

The company stated it will manage all commercialization and regulatory submissions across key global markets.

Management stated the deal supports corporate expansion.

The business stated this partnership directly aligns with its ongoing Pivot to Growth corporate strategy.

This strategic framework aims to increase broader market access to various biologic medicines globally.